Oncology Precision Medicine Market Size to Hit USD 364 Billion by 2035 | Roots Analysis

News provided by

Jan 18, 2024, 10:30 ET

According to a recently published report by Roots Analysis, the growing prevalence of cancer worldwide has led to a surge in the demand for tailored therapies to treat patients, which is anticipated to drive the market.

LONDON, Jan. 18, 2024 /PRNewswire/ --

Global Oncology Precision Medicine Market Overview

The global oncology precision medicine market is growing exponentially; it is estimated to be worth USD 130 billion in 2023 and is anticipated to reach USD 364 billion by 2035. It is expected to grow at a compounded annual growth rate (CAGR) of 8.93% during the forecast period from 2023 to 2035.

Precision medicine in oncology refers to the study of utilizing an individual's genetic data to develop a tailored treatment plan according to the molecular makeup of their cancer. In recent years, cancer has been the most common cause of death across the globe. According to the American Cancer Society report, in 2022, an estimated 1.9 million new cancer cases have been diagnosed worldwide, and around 609,360 deaths have occurred due to cancer. Presently, numerous conventional drug approaches have been developed, including surgical methods, chemotherapy, and radiation therapies. These cancer treatment approaches are predicted to be incompetent to fight against intrinsic carcinogenic genetic abnormalities that arise from patient-specific mutations in oncogenesis tumor suppressor genes. To address these concerns, the concept of precision medicine has been introduced, which involves the utilization of genomic knowledge for the development of gene-target therapeutics. It is interesting to note here that several precision centers, such as MD Anderson Cancer Center in the US, Mayo Clinic Cancer Center in the United States, and Memorial Sloan Kettering Cancer Center in New York, offer advanced treatment and technologies that are ideal for patients having difficult to treat cancer forms. Owing to the significance of precision medicines and ongoing technological advances, the oncology precision medicine market will witness substantial growth during the forecast period.

Download Free PDF Brochure:

https://www.rootsanalysis.com/reports/oncology-precision-medicine-market/request-sample.html

Oncology Precision Medicine Market Report Scope:

Report Coverage	Details
Market Revenue in 2023	USD 130 billion
Estimated value by 2035	USD 364 billion
Growth rate	CAGR of 8.93%
Forecast Period	2023 to 2035
Segments Covered	Distribution by Type of Cancer Targeted, Route of Administration, Drug Class, Type of Molecule
Geographies Covered	North America (US, Canada), Europe (France, Germany, Italy, Spain and UK), Asia (China, Japan, Korea and India), Middle East and North America (UAE, Israel, Qatar, Rest of Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America
Report Coverage	Revenue Forecast, Competitive Landscape, Growth Factors, Drivers, Restraints and Trends

Market Drivers

The market is propelled by the increasing incidence of cancer across the globe and the growing demand for tailored therapies to treat intrinsic cancer that are not cured with existing methods. The advancements in genomic technologies, such as next-generation sequencing, enabled the identification of genetic mutations, allowing researchers to develop target-based therapies according to specific genomic profiles. Further, the oncology precision market is also driven by a growing emphasis on personalized medicines to treat individuals suffering from cancers.

Market Restraints

Several factors that restrict the growth of the market include the high cost of precision medicines and reimbursement challenges. In some regions, reimbursement policies may not cover the cost of targeted therapies and genetic testing, leading to financial burdens on patients. Precision medicines rely on data analysis and collection for detailed study of genomics. The lack of standardization may lead to data privacy and security concerns, resulting in slowing down the market growth.

Growth Factors

Several factors that are contributing to the growth of the market include a supportive regulatory framework and rising partnerships between key market players. The growing demand of patients for personalized therapies has led to the adoption of tailored therapies in the oncology field, which is anticipated to drive the market in the future. Moreover, ongoing research efforts for the identification and validation of biomarkers for detailed analysis of patient genomics to develop therapies are a major growth factor that drives the market.

Recent Developments in Continuous Manufacturing Market

It is interesting to note here that the oncology precision medicine market witnesses several collaborations and development activities, some of which are listed below:

In September 2023, Exscientia and Merck entered into a licensing agreement to provide its AI-powered precision drug design and discovery-driven technologies. The collaboration will enable Merck to emphasize the development of drug design for neuroinflammatory and oncological disorders.
In August 2023, IDEAYA Biosciences announced the FDA clearance of an investigational new drug application of GSK101 (IDE705). GlaxoSmithKline has sponsored this clinical trial for the treatment of cancer patients with BRCA, homologous recombination, and homologous recombination deficiency mutations.
In April 2023, Tango Therapeutics received IND clearance from the FDA for TNG260 (a Co-repressor of Repressor Element-1 Silencing Transcription) to treat STK11-mutant cancers.

Request Free Sample PDF Copy at:

https://www.rootsanalysis.com/reports/oncology-precision-medicine-market/request-sample.html

Oncology Precision Medicine Market Segments

Based on the type of cancer targeted, oncology precision medicine is segmented into bladder cancer, blood / hematologic cancer, breast cancer, cervical cancer, gastrointestinal cancer, head and neck squamous cell cancer, lung cancer, skin cancer, and others.

Blood / hematologic cancer will dominate the market and is anticipated to capture 27.25% of the revenue share by 2035.
Lung cancer will grow during the forecast period at a higher CAGR of 11.32%

Based on the route of administration, the oncology precision medicine market is segmented into oral, intravenous, and others.

Based on the route of administration, intravenous will dominate the market, capturing 56% of the overall revenue share by 2035.
The oral route will grow at a higher CAGR of 9.18% during the forecast period.

Based on the type of molecules, the oncology precision medicine market is segmented into small molecules and biologics.

Based on the type of molecules, oncology precision medicine is dominated by small molecules and is poised to hold 51.72% of the overall revenue share by 2035.
Small molecules will grow at a higher CAGR of 10.63% during the forecast period.

Based on Drug Class, the oncology precision medicine market is segmented into kinase inhibitors, enzyme inhibitors, immune checkpoint inhibitors, and others.

Based on the drug class, the kinase inhibitor will dominate the market, capturing 50.60% of the overall revenue share by 2035.
Enzyme inhibitors will grow at a higher compounded annual growth rate (CAGR) of 11.43% during the forecast period.

Based on the key geographical region, the oncology precision medicine market is segmented into North America (US, Canada), Europe (France, Germany, Italy, Spain, and UK), Asia (China, Japan, Korea, and India), Middle East and North Africa (UAE, Israel, Qatar and Rest of the Middle East and North Africa) and Latin America (Brazil, Argentina, Chile and Rest of Latin America)

Based on the key geographical region, the oncology precision medicine market will be dominated by North America, holding 46.36% of the revenue share by 2035.
In Asia-Pacific, the oncology precision medicine market will grow at a higher compounded annual growth rate of 9.99% during the forecast period.

Key Companies Profiled

The oncology precision medicine market report also includes detailed profiles of key players (listed below) that provide solutions to cell line development services.

AbbVie
Anticancer Bioscience
Astellas Pharma
AstraZeneca
Bayer
Blueprint Medicines
Bristol Myers Squibb
Eli Lilly
Erasca
Genentech
GlaxoSmithKline
Hutchmed
IDEAYA Biosciences
Jiangsu Hengrui Pharmaceuticals
Johnson & Johnson Innovative Medicine
Merck
Novartis
Pfizer
Repare Therapeutics
Roche
Seagen
SpringWorks Therapeutics
Takeda Pharmaceutical
VERAXA Biotech GmbH
VRise Therapeutics

Browse Complete Report at:

https://www.rootsanalysis.com/reports/oncology-precision-medicine-market.html

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report gives stakeholders a pulse on the spectrometry market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Don't Miss Out on Other Interesting Titles:

Precision Medicine Software Market - The precision medicine software market is estimated to be worth $18 million in 2021 and is expected to grow at compounded annual growth rate (CAGR) of 30% during the forecast period.

Genome Editing Market - The global genome editing market size for technologies is estimated to be worth USD 3.5 billion in 2023 and is expected to grow at CAGR of 12.6% during the forecast period (2023-2035).

Liquid Biopsy Market - The global liquid biopsy market size is estimated to be worth $ 5.4 billion in 2023 and is expected to grow at compounded annual growth rate (CAGR) of 15.2%, during the forecast period.

Antibody Discovery Market – The global antibody discovery market size is estimated to be worth over $1.6 billion in 2023 and is expected to grow at a compounded annual growth rate (CAGR) of 12.0% during the forecast period.

mRNA Vaccine and Therapeutics Market - The global mRNA vaccine and therapeutics market size was estimated to be worth over USD 51 billion in 2022; non COVID-19 indications will drive the market growth during the forecast period 2023-2035.

About Roots Analysis

Roots Analysis is a global leader in the pharma/biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists, and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research/consulting services dedicated to serving our clients in the best possible way.

Contact Us:
Gaurav Chaudhary
Roots Analysis
+1 (415) 800 3415
Email: gaurav.chaudhary@rootsanalysis.com
Web: https://www.rootsanalysis.com/
Blog: https://www.rootsanalysis.com/blog/
Press Release: https://www.rootsanalysis.com/press-releases.html
Follow Us: LinkedIn| Twitter